LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

LLY

910.17

+0.51%↑

UNH

569.99

-0.12%↓

NVO

116.46

-0.73%↓

JNJ

163.54

+0.57%↑

ABBV

188.97

+1.46%↑

Начало・Списък с акции・Cara Therapeutics Inc

Cara Therapeutics Inc

Отворен

Сектор Здравеопазване

0.26

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

0.25

Максимум

0.26

Ключови измерители
By Trading Economics
Продажби	3M
EPS	-0.59
Служители	55

Дивиденти
By Dow Jones
Следващи печалби	11.11.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-2.3M 46M
Предишно отваряне	0.26
Предишно затваряне	0.26

Настроения в новините

By Acuity

29%

71%

69 / 366 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Weak Bullish Evidence

0.2599 / 0.2693 Подкрепа & съпротива

Cara Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.10.2024 г., 23:17 ч. UTC

Топ новини

Australian Consumer Confidence Highest Since Early 2023

21.10.2024 г., 20:42 ч. UTC

Печалби

SAP 3Q Revenue, Profit Climb on AI Demand; Outlook Raised

21.10.2024 г., 22:57 ч. UTC

Печалби

Ping An Insurance: Higher Income From Healthcare, Senior-Care Services Supported Results >2318.HK

21.10.2024 г., 22:57 ч. UTC

Печалби

Ping An Insurance 9-Mos Rev CNY861.8B ; Up 8.7% on Year >2318.HK

21.10.2024 г., 22:57 ч. UTC

Печалби

Ping An Insurance 9-Mos Net CNY119.2B; Up 36.1% on Year >2318.HK

21.10.2024 г., 22:10 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Webjet Looks Like an M&A Target, But Bids Unlikely Soon -- Market Talk

21.10.2024 г., 21:02 ч. UTC

Придобивния, сливания и поглъщания

Sanofi Deal Jitters Imperil Stock's Big Rebound -- Barrons.com

21.10.2024 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

21.10.2024 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

21.10.2024 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

21.10.2024 г., 20:32 ч. UTC

Печалби

Nucor: The Earnings of the Raw Materials Segment Are Expected to Increase in 4Q Compared to 3Q >NUE

21.10.2024 г., 20:31 ч. UTC

Печалби

Nucor: Expect Consolidated Net Earnings Attributable to Nucor Stockholders in 4Q to Decrease >NUE

21.10.2024 г., 20:30 ч. UTC

Печалби

Nucor 3Q Total Tons Shipped to Outside Customers Down 1% >NUE

21.10.2024 г., 20:30 ч. UTC

Печалби

Nucor 3Q Steel Mills Total Shipments 5.72M Tons >NUE

21.10.2024 г., 20:30 ч. UTC

Печалби

Nucor 3Q Average Sales Price Per Ton Down 15% >NUE

21.10.2024 г., 20:30 ч. UTC

Печалби

Nucor 3Q EPS $1.05 >NUE

21.10.2024 г., 20:30 ч. UTC

Печалби

Nucor 3Q Sales $7.44B >NUE

21.10.2024 г., 20:30 ч. UTC

Печалби

Nucor 3Q Net $249.9M >NUE

21.10.2024 г., 20:20 ч. UTC

Придобивния, сливания и поглъщания

Glendon Capital Filing Mentions Reuters Article About Glendon Opposition to Verizon Deal

21.10.2024 г., 20:20 ч. UTC

Топ новини

Nvidia Reaches $3.5 Trillion Market Value. It's Right on Apple's Heels. -- Barrons.com

21.10.2024 г., 20:19 ч. UTC

Придобивния, сливания и поглъщания

Frontier Communications Shareholder Glendon Capital Will Continue to Engage in Talks With Relevant Parties About Sale to Verizon

21.10.2024 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

21.10.2024 г., 20:14 ч. UTC

Топ новини

S&P 500, Dow Slip; Bond Yields Rise -- WSJ

21.10.2024 г., 20:10 ч. UTC

Печалби

SAP Backs 2024 Cloud Revenue EUR17B-EUR17.3B >SAP

21.10.2024 г., 20:10 ч. UTC

Печалби

SAP Raises 2024 Cloud and Software Revenue View to EUR29.5B-EUR29.8B >SAP

21.10.2024 г., 20:08 ч. UTC

Печалби

SAP Sees Exiting 2024 at Headcount Slightly Ahead of Year-End 2023 >SAP

21.10.2024 г., 20:07 ч. UTC

Печалби

SAP 3Q Cloud and Software Revenue EUR7.43B >SAP

21.10.2024 г., 20:07 ч. UTC

Печалби

SAP 3Q Software Licenses Revenue EUR280M>SAP

21.10.2024 г., 20:06 ч. UTC

Печалби

SAP 3Q Adj EPS EUR1.23 >SAP

21.10.2024 г., 20:06 ч. UTC

Печалби

SAP 3Q EPS EUR1.25 >SAP

Сравнение с други в отрасъла

Ценова промяна

Cara Therapeutics Inc Прогноза

Консенсусна оценка

By TipRanks

0 ratings

Купи

Задържане

Продай

Според 0 анализатори, дали борсови рейтинги на Cara Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

0.2599 / 0.2693Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bullish.

There are no events.

Настроение

By Acuity

69 / 366 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

EBITDA

Оперативна печалба

Относно Cara Therapeutics Inc

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.